Logo image of CPRX

CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock - Currency: USD

21.03  -0.42 (-1.96%)

After market: 21.47 +0.44 (+2.09%)

Fundamental Rating

8

CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make CPRX suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

CPRX had positive earnings in the past year.
In the past year CPRX had a positive cash flow from operations.
Each year in the past 5 years CPRX has been profitable.
CPRX had a positive operating cash flow in each of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

CPRX has a better Return On Assets (21.71%) than 97.85% of its industry peers.
CPRX's Return On Equity of 24.85% is amongst the best of the industry. CPRX outperforms 97.13% of its industry peers.
With an excellent Return On Invested Capital value of 21.96%, CPRX belongs to the best of the industry, outperforming 97.85% of the companies in the same industry.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is significantly above the industry average of 14.97%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.96%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.71%
ROE 24.85%
ROIC 21.96%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

CPRX has a better Profit Margin (36.91%) than 97.67% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
With an excellent Operating Margin value of 43.27%, CPRX belongs to the best of the industry, outperforming 99.46% of the companies in the same industry.
CPRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 86.11%, CPRX belongs to the best of the industry, outperforming 89.61% of the companies in the same industry.
CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 43.27%
PM (TTM) 36.91%
GM 86.11%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
CPRX has more shares outstanding than it did 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CPRX has an Altman-Z score of 16.41. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
CPRX's Altman-Z score of 16.41 is amongst the best of the industry. CPRX outperforms 91.94% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.41
ROIC/WACC2.26
WACC9.71%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CPRX has a Current Ratio of 6.14. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.14, CPRX is in the better half of the industry, outperforming 62.19% of the companies in the same industry.
A Quick Ratio of 5.96 indicates that CPRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 5.96, CPRX is doing good in the industry, outperforming 62.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.14
Quick Ratio 5.96
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 112.16% over the past year.
The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.96%.
The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)112.16%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%136.84%
Revenue 1Y (TTM)29.96%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%43.56%

3.2 Future

Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.40% on average per year.
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 12.18% on average per year.
EPS Next Y13.68%
EPS Next 2Y14.77%
EPS Next 3Y13.44%
EPS Next 5Y29.4%
Revenue Next Year15.89%
Revenue Next 2Y12.29%
Revenue Next 3Y12.18%
Revenue Next 5Y12.18%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 13.39 indicates a correct valuation of CPRX.
Based on the Price/Earnings ratio, CPRX is valued cheaper than 96.24% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.50, CPRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 12.19, the valuation of CPRX can be described as correct.
Based on the Price/Forward Earnings ratio, CPRX is valued cheaply inside the industry as 95.88% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 36.44. CPRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.39
Fwd PE 12.19
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 98.03% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CPRX is valued cheaper than 97.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.59
EV/EBITDA 7.56
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CPRX's earnings are expected to grow with 13.44% in the coming years.
PEG (NY)0.98
PEG (5Y)0.39
EPS Next 2Y14.77%
EPS Next 3Y13.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (7/18/2025, 8:00:01 PM)

After market: 21.47 +0.44 (+2.09%)

21.03

-0.42 (-1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners82.81%
Inst Owner Change0.61%
Ins Owners5.57%
Ins Owner Change-1.1%
Market Cap2.57B
Analysts88.57
Price Target34.68 (64.91%)
Short Float %7.13%
Short Ratio6.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.58%
Min EPS beat(2)27.41%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)23.15%
Min EPS beat(4)12.87%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)20.71%
EPS beat(12)11
Avg EPS beat(12)13.76%
EPS beat(16)12
Avg EPS beat(16)8.39%
Revenue beat(2)2
Avg Revenue beat(2)4.52%
Min Revenue beat(2)3.61%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)4.7%
Min Revenue beat(4)2.23%
Max Revenue beat(4)7.55%
Revenue beat(8)7
Avg Revenue beat(8)3.29%
Revenue beat(12)11
Avg Revenue beat(12)3.49%
Revenue beat(16)13
Avg Revenue beat(16)3.39%
PT rev (1m)0%
PT rev (3m)0.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.21%
EPS NY rev (1m)0%
EPS NY rev (3m)3.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
Industry RankSector Rank
PE 13.39
Fwd PE 12.19
P/S 4.8
P/FCF 9.59
P/OCF 9.57
P/B 3.23
P/tB 3.97
EV/EBITDA 7.56
EPS(TTM)1.57
EY7.47%
EPS(NY)1.73
Fwd EY8.2%
FCF(TTM)2.19
FCFY10.43%
OCF(TTM)2.2
OCFY10.44%
SpS4.38
BVpS6.51
TBVpS5.3
PEG (NY)0.98
PEG (5Y)0.39
Profitability
Industry RankSector Rank
ROA 21.71%
ROE 24.85%
ROCE 29.02%
ROIC 21.96%
ROICexc 80.84%
ROICexgc 252.85%
OM 43.27%
PM (TTM) 36.91%
GM 86.11%
FCFM 50.05%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexcg growth 3Y8.72%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.94%
Cap/Sales 0.07%
Interest Coverage 161.46
Cash Conversion 99.54%
Profit Quality 135.58%
Current Ratio 6.14
Quick Ratio 5.96
Altman-Z 16.41
F-Score6
WACC9.71%
ROIC/WACC2.26
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)112.16%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%136.84%
EPS Next Y13.68%
EPS Next 2Y14.77%
EPS Next 3Y13.44%
EPS Next 5Y29.4%
Revenue 1Y (TTM)29.96%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%43.56%
Revenue Next Year15.89%
Revenue Next 2Y12.29%
Revenue Next 3Y12.18%
Revenue Next 5Y12.18%
EBIT growth 1Y195.42%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year19.29%
EBIT Next 3Y19.23%
EBIT Next 5YN/A
FCF growth 1Y123.91%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y124.02%
OCF growth 3Y58.35%
OCF growth 5Y47.28%